- According to data from the London Stock Exchange Group (LSEG), the Hong Kong IPO market is experiencing a structural marginal recovery. Currently, about 10 foreign companies from Indonesia, Korea, Singapore, and other regions have submitted listing applications, marking the highest level since 2020.
- The companies planning to list show significant industry diversification, covering cutting-edge sectors such as biotechnology, blockchain infrastructure, and modern logistics. Companies like Singapore's Engine Biosciences, the US's NiKang Therapeutics, and Malaysia's Teleport are exploring listing options in Hong Kong.
- The head of Global Issuer Services at the Hong Kong Stock Exchange (0388:HK) noted that the logic of overseas companies raising funds in Hong Kong is shifting from a sole focus on Greater China business connections to a deeper strategic expansion that fully engages global funds and core Asian institutional investors.
Liquidity Recovery in the IPO Market and Inflow of Foreign Capital
The liquidity of the current Hong Kong stock market is in a cyclical recovery phase. According to data from the London Stock Exchange Group, by 2025, Hong Kong and mainland Chinese companies are expected to raise a total of $36.4 billion through 110 IPO transactions in Hong Kong. If the scope is expanded to global issuers, the Hong Kong Stock Exchange maintained its global leading position last year with 115 transactions and a total fundraising amount of $37.4 billion. This abundant underlying liquidity pool is rekindling international capital's confidence in pricing in the Hong Kong market. As some macro uncertainties diminish, global funds and hedge funds are reassessing the allocation weight of Asian equity assets, directly providing a solid buyer base for non-Greater China foreign companies to raise funds in Hong Kong.
Evolution of Cross-Border Corporate Capital Operations
Looking back at the internationalization process of the Hong Kong capital market, since 2000, foreign companies have raised approximately $22 billion through 156 transactions, with the overall scale still limited. However, the current listing boom shows a multidimensional evolution in capital operation structures. Companies are no longer limited to traditional IPOs, with simultaneous dual listings and subsequent dual listings gradually becoming important tools for multinational companies to optimize their balance sheets. A representative from the Hong Kong Stock Exchange stated that Hong Kong's appeal has surpassed the rigid requirement of exposure to mainland business. Even overseas companies without substantial operational entities in Asia can efficiently raise funds through Hong Kong's comprehensive underwriting network, marking a redefinition of Hong Kong's financing function as an independent international offshore financial center.
Valuation and Industry Distribution of Key Prospective Listed Companies
The profile of companies in the current foreign listing reserve in Hong Kong has fundamentally changed. Unlike about fifteen years ago, when traditional consumer brands like Prada (1913:HK) and Samsonite (1910:HK) dominated, the current candidate list is highly concentrated in the new economy sector. Among the 12 potential foreign candidate companies expected in 2026 are US blockchain infrastructure provider Blockdaemon and UK biopharmaceutical company Allergy Therapeutics. Notably, Switzerland-based Syngenta Group is preparing to advance a listing plan in the second half of this year, potentially raising up to $10 billion. If such large-scale, high-tech barrier giants successfully list, it will significantly enhance Hong Kong's influence in global core asset pricing.
Benchmarking Effect of Biotechnology and Frontier Technology Sectors
The biotechnology sector is becoming a core engine for the Hong Kong Stock Exchange to attract international targets. Since the reform of listing rules, Hong Kong has gradually established a valuation system parallel to Nasdaq (NDAQ:US) in terms of analyst coverage breadth, peer comparability, and institutional investor recognition. Early engagement with startup biotechnology companies like Engine Biosciences and NiKang Therapeutics has validated Hong Kong's capacity to meet the financing needs of long-cycle, high-risk R&D enterprises. The active involvement of investment banks like Citigroup (C:US) further completes the closed loop from asset to capital end, enabling Hong Kong to provide a more resilient valuation anchor for global frontier technology companies.
Strategic Expansion of the Hong Kong Stock Exchange and Geopolitical Capital Considerations
From a broader perspective, the Hong Kong Stock Exchange's strategy to attract foreign listings is at a critical acceleration phase. Against the backdrop of complex global geopolitical capital restructuring, international companies need to diversify the regulatory and liquidity risks of a single listing location. With its institutional advantages spanning East and West and the broadest investor base, Hong Kong is becoming the preferred platform for multinational companies to build a capital firewall. As mainland Chinese institutional investors continue to inject incremental funds through the connectivity mechanism, Hong Kong can not only meet overseas companies' financing needs in US dollars and Hong Kong dollars but also open a strategic channel for them to access substantial RMB allocation funds.
